Fig. 5. 87G7 protects hamsters from challenge with D614G SARS-CoV-2 and Gamma, Delta and Omicron variants.

87G7 or isotype control mAb was administered intraperitoneally (10 mg/kg body weight or 20mg/kg for Omicron-challenged hamsters) into groups of Syrian hamsters (n = 5, and n = 6 for Omicron groups) at 24 hours before (A, B, C) or 12 hours after virus challenge (D, E, F). Hamsters were challenged intranasally with 10⁴ TCID50 of D614G SARS-CoV-2, Beta, Gamma or Omicron. Four days after challenge hamsters were euthanized, and infectious SARS-CoV-2 titer in lung homogenates and nasal cavity were evaluated by TCID50 measurement (A and D). Lung and nasal cavity were examined for lesions by histopathological scoring and presence of viral antigen by immunohistochemistry (B, C and E, F; Table S3-S5, Figure S7-S10). The mean values ± SEM of all data points were shown. Mann-Whitney U test was used to evaluate the statistical difference between the 87G7 and isotype-treated groups (**p<0.01, *p<0.05, ns p>0.05).